Piper Jaffray Companies reaffirmed their hold rating on shares of Iqvia (NYSE:IQV) in a research note issued to investors on Thursday. The firm currently has a $103.00 target price on the medical research company’s stock.
Several other equities analysts also recently weighed in on the company. Mitsubishi UFJ Financial Group initiated coverage on Iqvia in a research report on Friday, December 15th. They set a neutral rating and a $112.00 target price on the stock. KeyCorp restated a sector weight rating and issued a $100.00 price objective on shares of Iqvia in a report on Friday, November 10th. Morgan Stanley raised their price objective on Iqvia from $96.00 to $121.00 and gave the stock an overweight rating in a report on Thursday, November 9th. Barclays raised their price objective on Iqvia from $100.00 to $120.00 and gave the stock an overweight rating in a report on Friday, October 27th. Finally, Zacks Investment Research upgraded Iqvia from a hold rating to a buy rating and set a $121.00 price objective on the stock in a report on Tuesday, October 31st. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $110.02.
Iqvia (IQV) opened at $101.72 on Thursday. Iqvia has a 12-month low of $75.94 and a 12-month high of $110.67. The firm has a market capitalization of $21,183.34, a PE ratio of 22.07, a P/E/G ratio of 1.81 and a beta of 0.61. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.22 and a current ratio of 1.19.
Iqvia (NYSE:IQV) last released its earnings results on Wednesday, February 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The business had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter last year, the company posted $1.09 earnings per share. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. analysts predict that Iqvia will post 4.1 EPS for the current fiscal year.
In other news, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total value of $999,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Connaughton sold 1,163,191 shares of the stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $118,645,482.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,727,078 shares of company stock valued at $890,124,079. Insiders own 6.40% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Halsey Associates Inc. CT acquired a new stake in shares of Iqvia in the fourth quarter valued at about $18,226,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in shares of Iqvia in the fourth quarter valued at about $11,695,000. MetLife Investment Advisors LLC acquired a new stake in shares of Iqvia in the fourth quarter valued at about $4,410,000. Jump Trading LLC acquired a new stake in shares of Iqvia in the fourth quarter valued at about $326,000. Finally, Pacific Grove Capital LP acquired a new stake in shares of Iqvia in the fourth quarter valued at about $5,163,000. Institutional investors and hedge funds own 96.09% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/19/piper-jaffray-companies-reaffirms-hold-rating-for-iqvia-iqv-2.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.